PPCB Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 21:57):

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia...

Stats
Dagens volum	13.19M
Gjennomsnittsvolum	4.39M
Markedsverdi	2.63B
EPS	$-0.0449 ( 2023-11-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0800
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-05	Zelinger Josef	Buy	15 000 000	Common Stock Purchase Warrant
2021-08-17	Kenyon Julian Norman	Buy	3 420 000	Common stock, par value $0.001
2021-08-17	Nathanielsz James Andrew	Buy	5 928 000	Common stock, par value $0.001
2021-08-17	Nathanielsz James Andrew	Buy	2 800 000	Common stock, par value $0.001
2021-08-17	Zelinger Josef	Sell	0	Common stock, par value $0.001

INSIDER POWER
100.00
Last 22 transactions
Buy: 280 061 820 \| Sell: 580 500

Propanc Biopharma, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Propanc Biopharma, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-28 841.00 (0.00 %)
EPS:	$-1.530

FY	2023
Omsetning:	$0
Bruttogevinst:	$-28 841.00 (0.00 %)
EPS:	$-1.530

FY	2022
Omsetning:	$0
Bruttogevinst:	$-28 366.00 (0.00 %)
EPS:	$-1.530

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.800

Financial Reports:

No articles found.

Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.